Heart Failure | Reduced Ejection Fraction | Treatment Algorithms: Claims Data Analysis | US | 2024

Heart failure with reduced ejection fraction (HFrEF) has a well-established drug treatment with a wealth of supporting evidence from clinical trials. ACE inhibitors, or ARBs, beta blockers, and loop diuretics are typically used in the first-line treatment of HFrEF patients. Given the heavily genericized nature of the market, branded agents, such as Novartis’ Entresto, Amgen’s Corlanor, AstraZeneca’s Farxiga, and Eli Lilly’s Jardiance, have had difficulty establishing a foothold. However, the use of Farxiga, Jardiance, and Entresto has grown steadily since their launch. This analysis offers insight into U.S. prescribing patterns in the HFrEF subpopulation.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed HFrEF patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed HFrEF patients?
• How have Entresto, Farxiga, Jardiance, and Verquvo been integrated into the treatment algorithm, and what are their source of business?
• What percentage of HFrEF patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy in one year of diagnosis?
• What percentage of HFrEF patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States

Key companies: Pfizer, Merck & Co., Novartis, GSK, AstraZeneca, Johnson & Johnson, Eli Lilly, Boehringer Ingelheim, Amgen

Key drugs: ACE inhibitors, ARBs, beta blockers, diuretics, aldosterone antagonists, nitrates, Entresto, Corlanor, Farxiga, Jardiance, Verquvo

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses